Details of the Drug
General Information of Drug (ID: DM6GWAC)
Drug Name |
DDATHF
|
|||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Synonyms |
DATHF; 95693-76-8; 5,10-dideazatetrahydrofolate; 5,10-Dideaza-5,6,7,8-tetrahydrofolic acid; 5,10-dideazatetrahydrofolic acid; L-Glutamic acid,N-[4-[2-(2-amino-3,4,5,6,7,8-hexahydro-4-oxopyrido[2,3-d]pyrimidin-6-yl)ethyl]benzoyl]-; L-Glutamic acid, N-(4-(2-(2-amino-1,4,5,6,7,8-hexahydro-4-oxopyrido(2,3-d)pyrimidin-6-yl)ethyl)benzoyl)-; C21H25N5O6; AC1L2XXH; Pyrido(2,3-d)pyrimidine, L-glutamic acid deriv; CHEMBL142806; SCHEMBL9045915; ZUQBAQVRAURMCL-CVRLYYSRSA-N; 5,10-Dideazatetrahydrofolic Acid
|
|||||||||||||||||||
Indication |
|
|||||||||||||||||||
Drug Type |
Small molecular drug
|
|||||||||||||||||||
Structure | ||||||||||||||||||||
3D MOL | 2D MOL | |||||||||||||||||||
#Ro5 Violations (Lipinski): 1 | Molecular Weight (mw) | 443.5 | ||||||||||||||||||
Topological Polar Surface Area (xlogp) | 0.3 | |||||||||||||||||||
Rotatable Bond Count (rotbonds) | 9 | |||||||||||||||||||
Hydrogen Bond Donor Count (hbonddonor) | 6 | |||||||||||||||||||
Hydrogen Bond Acceptor Count (hbondacc) | 8 | |||||||||||||||||||
Chemical Identifiers |
|
|||||||||||||||||||
Cross-matching ID | ||||||||||||||||||||
Molecular Interaction Atlas of This Drug
Drug Therapeutic Target (DTT) |
|
|||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Molecular Interaction Atlas (MIA) | ||||||||||||||||||||||||||||||||
Molecular Expression Atlas of This Drug
The Studied Disease | Discovery agent | |||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ICD Disease Classification | N.A. | |||||||||||||||||||||||
|
||||||||||||||||||||||||
Molecular Expression Atlas (MEA) | ||||||||||||||||||||||||
References